Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Standard vs Renal Dosing of Piperacillin/Tazobactam in Septic Shock and Acute Renal Failure
NCT00816790Phase 4Terminated
- Sponsor
- Fraser Health
- Start
- Jan 2009
- Primary completion
- May 2011
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 4, randomised trial of piperacillin + tazobactam in septic shock (2 arms), sponsored by Fraser Health. Primary endpoints: Rate of patient accrual at 4 months and Protocol adherence at 4 months. Started Jan 2009; status: terminated.
02
Drugs
piperacillin + tazobactam
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT00816790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00816790.